621 related articles for article (PubMed ID: 33787832)
21. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York.
Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L
Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.
Nosyk B; Guh DP; Bansback NJ; Oviedo-Joekes E; Brissette S; Marsh DC; Meikleham E; Schechter MT; Anis AH
CMAJ; 2012 Apr; 184(6):E317-28. PubMed ID: 22410375
[TBL] [Abstract][Full Text] [Related]
23. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration.
Ching JH; Owens DK; Trafton JA; Goldhaber-Fiebert JD; Salomon JA
Addiction; 2021 Dec; 116(12):3494-3503. PubMed ID: 33999485
[TBL] [Abstract][Full Text] [Related]
24. Review of medication-assisted treatment for opioid use disorder.
Ghanem N; Dromgoole D; Hussein A; Jermyn RT
J Osteopath Med; 2022 Mar; 122(7):367-374. PubMed ID: 35285220
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder.
Enns B; Krebs E; Whitehurst DGT; Jutras-Aswad D; Le Foll B; Socias ME; Nosyk B;
Drug Alcohol Depend; 2023 Jun; 247():109893. PubMed ID: 37120920
[TBL] [Abstract][Full Text] [Related]
26. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
27. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: A systematic review.
Maglione MA; Raaen L; Chen C; Azhar G; Shahidinia N; Shen M; Maksabedian E; Shanman RM; Newberry S; Hempel S
J Subst Abuse Treat; 2018 Jun; 89():28-51. PubMed ID: 29706172
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder.
Qian G; Rao I; Humphreys K; Owens DK; Brandeau ML
Drug Alcohol Depend; 2023 Feb; 243():109762. PubMed ID: 36621198
[TBL] [Abstract][Full Text] [Related]
29. Financial factors and the implementation of medications for treating opioid use disorders.
Knudsen HK; Roman PM
J Addict Med; 2012 Dec; 6(4):280-6. PubMed ID: 22810057
[TBL] [Abstract][Full Text] [Related]
30. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
Connock M; Juarez-Garcia A; Jowett S; Frew E; Liu Z; Taylor RJ; Fry-Smith A; Day E; Lintzeris N; Roberts T; Burls A; Taylor RS
Health Technol Assess; 2007 Mar; 11(9):1-171, iii-iv. PubMed ID: 17313907
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment.
Maas J; Barton G; Maskrey V; Pinto H; Holland R
Drug Alcohol Depend; 2013 Dec; 133(2):494-501. PubMed ID: 23962419
[TBL] [Abstract][Full Text] [Related]
32. Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice.
Deyo-Svendsen M; Cabrera Svendsen M; Walker J; Hodges A; Oldfather R; Mansukhani MP
J Prim Care Community Health; 2020; 11():2150132720931720. PubMed ID: 32507023
[TBL] [Abstract][Full Text] [Related]
33. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
[TBL] [Abstract][Full Text] [Related]
34. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.
Uebelacker LA; Bailey G; Herman D; Anderson B; Stein M
J Subst Abuse Treat; 2016 Jul; 66():48-53. PubMed ID: 27211996
[TBL] [Abstract][Full Text] [Related]
35. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder.
Flam-Ross JM; Marsh E; Weitz M; Savinkina A; Schackman BR; Wang J; Madushani RWMA; Morgan JR; Barocas JA; Walley AY; Chrysanthopoulou SA; Linas BP; Assoumou SA
JAMA Netw Open; 2023 Sep; 6(9):e2329583. PubMed ID: 37703018
[TBL] [Abstract][Full Text] [Related]
36. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
Xu KY; Mintz CM; Presnall N; Bierut LJ; Grucza RA
JAMA Netw Open; 2022 May; 5(5):e2211363. PubMed ID: 35536575
[TBL] [Abstract][Full Text] [Related]
38. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.
Ma J; Bao YP; Wang RJ; Su MF; Liu MX; Li JQ; Degenhardt L; Farrell M; Blow FC; Ilgen M; Shi J; Lu L
Mol Psychiatry; 2019 Dec; 24(12):1868-1883. PubMed ID: 29934549
[TBL] [Abstract][Full Text] [Related]
39. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence.
Gisev N; Shanahan M; Weatherburn DJ; Mattick RP; Larney S; Burns L; Degenhardt L
Addiction; 2015 Dec; 110(12):1975-84. PubMed ID: 26212260
[TBL] [Abstract][Full Text] [Related]
40. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder.
Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT
JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
